A number of studies also sought to investigate the predictive power of HDL-C or ApoA-I levels in subsets of cancers and found that, when combined with other traditional cancer biomarkers cancer antigen 125 (CA125) and transthyretin (TTR), either ApoA-I or HDL-C levels significantly increased the power of these panels to predict patient prognosis (52, 54–58). Here, APOA1 is linked to cancer.